Aerie Phama misses Q2 analyst estimates but sees gains for glaucoma drug
Aerie Pharmaceuticals saw its losses exceed expectations in the second quarter, but expects to make $20 to $30 million on its glaucoma drug in 2018.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
